Clinical effectiveness of neuraminidase inhibitors—oseltamivir, zanamivir, laninamivir, and peramivir—for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010–2011 influenza season in Japan
Abstract The clinical effectiveness of the newly released neuraminidase inhibitors (NAIs) laninamivir and peramivir has not been sufficiently evaluated in influenza-infected patients in clinical and practical settings. In this study, we analyzed the clinical data of 211 patients infected with influe...
Gespeichert in:
| Veröffentlicht in: | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2012, Vol.18 (6), p.858-864 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 864 |
|---|---|
| container_issue | 6 |
| container_start_page | 858 |
| container_title | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |
| container_volume | 18 |
| creator | Shobugawa, Yugo Saito, Reiko Dapat, Clyde Dapat, Isolde Caperig Kondo, Hiroki Saito, Kousuke Sato, Isamu Kawashima, Takashi Suzuki, Yasushi Suzuki, Hiroshi |
| description | Abstract The clinical effectiveness of the newly released neuraminidase inhibitors (NAIs) laninamivir and peramivir has not been sufficiently evaluated in influenza-infected patients in clinical and practical settings. In this study, we analyzed the clinical data of 211 patients infected with influenza A virus subtype H3N2 (A(H3N2)) and 45 patients infected with influenza A virus subtype H1N1pdm (A(H1N1)pdm09) who received the NAIs oseltamivir, zanamivir, laninamivir, or peramivir during the 2010-2011 influenza season. The duration of fever from the first dose of the NAI to fever alleviation to |
| doi_str_mv | 10.1007/s10156-012-0428-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1273452709</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1341321X12702118</els_id><sourcerecordid>1273452709</sourcerecordid><originalsourceid>FETCH-LOGICAL-c570t-c95abd6918be04129c4756a53290ca84123116526e639e087b7ae60f1cc7a9673</originalsourceid><addsrcrecordid>eNp9ks1u1TAQhSMEoqXwAGyQl61EwOP8OAEJqboCCqrKApDYWY4zoS6JffEkV2pXfQd4wq55CBxyWxCLrjzjOd_YmjNJ8hj4M-BcPifgUJQpB5HyXFQp3El2Ic9kKmXF78Y4yyHNBHzZSR4QnXEOsqiq-8mOEGWe84rvJr9WvXXW6J5h16EZ7QYdEjHfMYdT0EOstpqQWXdqGzv6QFeXPz1hP8baxoan7EK767DXzt4k2rVsjWFJI9T5wMaAehzQjfMD1nX9hO5Cs8P9o-xEHPxBYgwncLBuB17PkvlT3r2INeYbwrDRcx4_TOPUnkcFG0-RCQ786vJHPOCfvoSavJs17_Vau4fJvU73hI-2517y-c3rT6uj9PjD23erw-PUFJKPqakL3bRlDVWDPAdRm1wWpS4yUXOjq3iTAZSFKLHMauSVbKTGkndgjNR1KbO9ZH_puw7--4Q0qsGSwT6OB_1ECoTM8kJIXkcpLFITPFHATq2DHXQ4V8DVbLJaTFbRZDWbrCAyT7btp2bA9oa4djUKxCKgWHJfMagzP4U4M7q168sFwjiZjY0QGYvOYGtD9EC13t5Kv_qPNtvF-obnSH_fVxQZ9XFezXkz4yi4AKiy37rQ3uk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1273452709</pqid></control><display><type>article</type><title>Clinical effectiveness of neuraminidase inhibitors—oseltamivir, zanamivir, laninamivir, and peramivir—for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010–2011 influenza season in Japan</title><source>MEDLINE</source><source>SpringerNature Journals</source><source>Alma/SFX Local Collection</source><creator>Shobugawa, Yugo ; Saito, Reiko ; Dapat, Clyde ; Dapat, Isolde Caperig ; Kondo, Hiroki ; Saito, Kousuke ; Sato, Isamu ; Kawashima, Takashi ; Suzuki, Yasushi ; Suzuki, Hiroshi</creator><creatorcontrib>Shobugawa, Yugo ; Saito, Reiko ; Dapat, Clyde ; Dapat, Isolde Caperig ; Kondo, Hiroki ; Saito, Kousuke ; Sato, Isamu ; Kawashima, Takashi ; Suzuki, Yasushi ; Suzuki, Hiroshi</creatorcontrib><description>Abstract The clinical effectiveness of the newly released neuraminidase inhibitors (NAIs) laninamivir and peramivir has not been sufficiently evaluated in influenza-infected patients in clinical and practical settings. In this study, we analyzed the clinical data of 211 patients infected with influenza A virus subtype H3N2 (A(H3N2)) and 45 patients infected with influenza A virus subtype H1N1pdm (A(H1N1)pdm09) who received the NAIs oseltamivir, zanamivir, laninamivir, or peramivir during the 2010-2011 influenza season. The duration of fever from the first dose of the NAI to fever alleviation to <37.5 °C was evaluated as an indicator of the clinical effectiveness of the NAIs in the influenza-infected patients. For the A(H3N2)-infected patients, Kaplan–Meier analysis showed the peramivir treatment group had the fastest time of fever alleviation to <37.5 °C (median 17.0 h, 95 % confidence interval [CI] 7.2–26.8 h) of the four treatment groups. No significant difference was found in the time to fever alleviation among the other antivirals, oseltamivir, zanamivir, and laninamivir. Results of multivariate analysis, using a Cox proportional-hazards model (hazard ratio 3.321) adjusted for the factors age, sex, body weight, vaccination status, time from onset to the clinic visit, and body temperature showed significantly faster fever alleviation in the peramivir treatment group compared with the oseltamivir treatment group. For the A(H1N1)pdm09-infected patients, only the oseltamivir and zanamivir treatment groups were compared, and no significant difference in time to alleviation of fever was observed between the two groups. Based on a cycling probe real-time polymerase chain reaction (PCR) assay, none of the A(H1N1)pdm09 strains in this study had the H275Y mutation conferring oseltamivir resistance. Further evaluation of the clinical effectiveness of the newly released NAIs for influenza-infected patients, including those infected with A(H1N1)pdm09, is needed.</description><identifier>ISSN: 1341-321X</identifier><identifier>EISSN: 1437-7780</identifier><identifier>DOI: 10.1007/s10156-012-0428-1</identifier><identifier>PMID: 22644080</identifier><language>eng</language><publisher>Japan: Elsevier Ltd</publisher><subject>Antiviral Agents - therapeutic use ; Child ; Child, Preschool ; Clinical effectiveness ; Cyclopentanes - therapeutic use ; Disease Outbreaks ; Enzyme Inhibitors - therapeutic use ; Female ; Fever alleviation ; Guanidines - therapeutic use ; Hematology, Oncology and Palliative Medicine ; Humans ; Infectious Diseases ; Influenza A Virus, H1N1 Subtype - isolation & purification ; Influenza A Virus, H3N2 Subtype - isolation & purification ; Influenza virus ; Influenza, Human - drug therapy ; Influenza, Human - epidemiology ; Influenza, Human - virology ; Japan - epidemiology ; Male ; Medical Microbiology ; Medicine ; Medicine & Public Health ; Neuraminidase - antagonists & inhibitors ; Neuraminidase inhibitors ; Observational study ; Original Article ; Oseltamivir - therapeutic use ; Treatment Outcome ; Virology ; Zanamivir - therapeutic use</subject><ispartof>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2012, Vol.18 (6), p.858-864</ispartof><rights>Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases</rights><rights>2012 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases</rights><rights>Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c570t-c95abd6918be04129c4756a53290ca84123116526e639e087b7ae60f1cc7a9673</citedby><cites>FETCH-LOGICAL-c570t-c95abd6918be04129c4756a53290ca84123116526e639e087b7ae60f1cc7a9673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10156-012-0428-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10156-012-0428-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22644080$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shobugawa, Yugo</creatorcontrib><creatorcontrib>Saito, Reiko</creatorcontrib><creatorcontrib>Dapat, Clyde</creatorcontrib><creatorcontrib>Dapat, Isolde Caperig</creatorcontrib><creatorcontrib>Kondo, Hiroki</creatorcontrib><creatorcontrib>Saito, Kousuke</creatorcontrib><creatorcontrib>Sato, Isamu</creatorcontrib><creatorcontrib>Kawashima, Takashi</creatorcontrib><creatorcontrib>Suzuki, Yasushi</creatorcontrib><creatorcontrib>Suzuki, Hiroshi</creatorcontrib><title>Clinical effectiveness of neuraminidase inhibitors—oseltamivir, zanamivir, laninamivir, and peramivir—for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010–2011 influenza season in Japan</title><title>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</title><addtitle>J Infect Chemother</addtitle><addtitle>J Infect Chemother</addtitle><description>Abstract The clinical effectiveness of the newly released neuraminidase inhibitors (NAIs) laninamivir and peramivir has not been sufficiently evaluated in influenza-infected patients in clinical and practical settings. In this study, we analyzed the clinical data of 211 patients infected with influenza A virus subtype H3N2 (A(H3N2)) and 45 patients infected with influenza A virus subtype H1N1pdm (A(H1N1)pdm09) who received the NAIs oseltamivir, zanamivir, laninamivir, or peramivir during the 2010-2011 influenza season. The duration of fever from the first dose of the NAI to fever alleviation to <37.5 °C was evaluated as an indicator of the clinical effectiveness of the NAIs in the influenza-infected patients. For the A(H3N2)-infected patients, Kaplan–Meier analysis showed the peramivir treatment group had the fastest time of fever alleviation to <37.5 °C (median 17.0 h, 95 % confidence interval [CI] 7.2–26.8 h) of the four treatment groups. No significant difference was found in the time to fever alleviation among the other antivirals, oseltamivir, zanamivir, and laninamivir. Results of multivariate analysis, using a Cox proportional-hazards model (hazard ratio 3.321) adjusted for the factors age, sex, body weight, vaccination status, time from onset to the clinic visit, and body temperature showed significantly faster fever alleviation in the peramivir treatment group compared with the oseltamivir treatment group. For the A(H1N1)pdm09-infected patients, only the oseltamivir and zanamivir treatment groups were compared, and no significant difference in time to alleviation of fever was observed between the two groups. Based on a cycling probe real-time polymerase chain reaction (PCR) assay, none of the A(H1N1)pdm09 strains in this study had the H275Y mutation conferring oseltamivir resistance. Further evaluation of the clinical effectiveness of the newly released NAIs for influenza-infected patients, including those infected with A(H1N1)pdm09, is needed.</description><subject>Antiviral Agents - therapeutic use</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Clinical effectiveness</subject><subject>Cyclopentanes - therapeutic use</subject><subject>Disease Outbreaks</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Female</subject><subject>Fever alleviation</subject><subject>Guanidines - therapeutic use</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Infectious Diseases</subject><subject>Influenza A Virus, H1N1 Subtype - isolation & purification</subject><subject>Influenza A Virus, H3N2 Subtype - isolation & purification</subject><subject>Influenza virus</subject><subject>Influenza, Human - drug therapy</subject><subject>Influenza, Human - epidemiology</subject><subject>Influenza, Human - virology</subject><subject>Japan - epidemiology</subject><subject>Male</subject><subject>Medical Microbiology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neuraminidase - antagonists & inhibitors</subject><subject>Neuraminidase inhibitors</subject><subject>Observational study</subject><subject>Original Article</subject><subject>Oseltamivir - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Virology</subject><subject>Zanamivir - therapeutic use</subject><issn>1341-321X</issn><issn>1437-7780</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9ks1u1TAQhSMEoqXwAGyQl61EwOP8OAEJqboCCqrKApDYWY4zoS6JffEkV2pXfQd4wq55CBxyWxCLrjzjOd_YmjNJ8hj4M-BcPifgUJQpB5HyXFQp3El2Ic9kKmXF78Y4yyHNBHzZSR4QnXEOsqiq-8mOEGWe84rvJr9WvXXW6J5h16EZ7QYdEjHfMYdT0EOstpqQWXdqGzv6QFeXPz1hP8baxoan7EK767DXzt4k2rVsjWFJI9T5wMaAehzQjfMD1nX9hO5Cs8P9o-xEHPxBYgwncLBuB17PkvlT3r2INeYbwrDRcx4_TOPUnkcFG0-RCQ786vJHPOCfvoSavJs17_Vau4fJvU73hI-2517y-c3rT6uj9PjD23erw-PUFJKPqakL3bRlDVWDPAdRm1wWpS4yUXOjq3iTAZSFKLHMauSVbKTGkndgjNR1KbO9ZH_puw7--4Q0qsGSwT6OB_1ECoTM8kJIXkcpLFITPFHATq2DHXQ4V8DVbLJaTFbRZDWbrCAyT7btp2bA9oa4djUKxCKgWHJfMagzP4U4M7q168sFwjiZjY0QGYvOYGtD9EC13t5Kv_qPNtvF-obnSH_fVxQZ9XFezXkz4yi4AKiy37rQ3uk</recordid><startdate>2012</startdate><enddate>2012</enddate><creator>Shobugawa, Yugo</creator><creator>Saito, Reiko</creator><creator>Dapat, Clyde</creator><creator>Dapat, Isolde Caperig</creator><creator>Kondo, Hiroki</creator><creator>Saito, Kousuke</creator><creator>Sato, Isamu</creator><creator>Kawashima, Takashi</creator><creator>Suzuki, Yasushi</creator><creator>Suzuki, Hiroshi</creator><general>Elsevier Ltd</general><general>Springer Japan</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2012</creationdate><title>Clinical effectiveness of neuraminidase inhibitors—oseltamivir, zanamivir, laninamivir, and peramivir—for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010–2011 influenza season in Japan</title><author>Shobugawa, Yugo ; Saito, Reiko ; Dapat, Clyde ; Dapat, Isolde Caperig ; Kondo, Hiroki ; Saito, Kousuke ; Sato, Isamu ; Kawashima, Takashi ; Suzuki, Yasushi ; Suzuki, Hiroshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c570t-c95abd6918be04129c4756a53290ca84123116526e639e087b7ae60f1cc7a9673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Antiviral Agents - therapeutic use</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Clinical effectiveness</topic><topic>Cyclopentanes - therapeutic use</topic><topic>Disease Outbreaks</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Female</topic><topic>Fever alleviation</topic><topic>Guanidines - therapeutic use</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Infectious Diseases</topic><topic>Influenza A Virus, H1N1 Subtype - isolation & purification</topic><topic>Influenza A Virus, H3N2 Subtype - isolation & purification</topic><topic>Influenza virus</topic><topic>Influenza, Human - drug therapy</topic><topic>Influenza, Human - epidemiology</topic><topic>Influenza, Human - virology</topic><topic>Japan - epidemiology</topic><topic>Male</topic><topic>Medical Microbiology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neuraminidase - antagonists & inhibitors</topic><topic>Neuraminidase inhibitors</topic><topic>Observational study</topic><topic>Original Article</topic><topic>Oseltamivir - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Virology</topic><topic>Zanamivir - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shobugawa, Yugo</creatorcontrib><creatorcontrib>Saito, Reiko</creatorcontrib><creatorcontrib>Dapat, Clyde</creatorcontrib><creatorcontrib>Dapat, Isolde Caperig</creatorcontrib><creatorcontrib>Kondo, Hiroki</creatorcontrib><creatorcontrib>Saito, Kousuke</creatorcontrib><creatorcontrib>Sato, Isamu</creatorcontrib><creatorcontrib>Kawashima, Takashi</creatorcontrib><creatorcontrib>Suzuki, Yasushi</creatorcontrib><creatorcontrib>Suzuki, Hiroshi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shobugawa, Yugo</au><au>Saito, Reiko</au><au>Dapat, Clyde</au><au>Dapat, Isolde Caperig</au><au>Kondo, Hiroki</au><au>Saito, Kousuke</au><au>Sato, Isamu</au><au>Kawashima, Takashi</au><au>Suzuki, Yasushi</au><au>Suzuki, Hiroshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical effectiveness of neuraminidase inhibitors—oseltamivir, zanamivir, laninamivir, and peramivir—for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010–2011 influenza season in Japan</atitle><jtitle>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</jtitle><stitle>J Infect Chemother</stitle><addtitle>J Infect Chemother</addtitle><date>2012</date><risdate>2012</risdate><volume>18</volume><issue>6</issue><spage>858</spage><epage>864</epage><pages>858-864</pages><issn>1341-321X</issn><eissn>1437-7780</eissn><abstract>Abstract The clinical effectiveness of the newly released neuraminidase inhibitors (NAIs) laninamivir and peramivir has not been sufficiently evaluated in influenza-infected patients in clinical and practical settings. In this study, we analyzed the clinical data of 211 patients infected with influenza A virus subtype H3N2 (A(H3N2)) and 45 patients infected with influenza A virus subtype H1N1pdm (A(H1N1)pdm09) who received the NAIs oseltamivir, zanamivir, laninamivir, or peramivir during the 2010-2011 influenza season. The duration of fever from the first dose of the NAI to fever alleviation to <37.5 °C was evaluated as an indicator of the clinical effectiveness of the NAIs in the influenza-infected patients. For the A(H3N2)-infected patients, Kaplan–Meier analysis showed the peramivir treatment group had the fastest time of fever alleviation to <37.5 °C (median 17.0 h, 95 % confidence interval [CI] 7.2–26.8 h) of the four treatment groups. No significant difference was found in the time to fever alleviation among the other antivirals, oseltamivir, zanamivir, and laninamivir. Results of multivariate analysis, using a Cox proportional-hazards model (hazard ratio 3.321) adjusted for the factors age, sex, body weight, vaccination status, time from onset to the clinic visit, and body temperature showed significantly faster fever alleviation in the peramivir treatment group compared with the oseltamivir treatment group. For the A(H1N1)pdm09-infected patients, only the oseltamivir and zanamivir treatment groups were compared, and no significant difference in time to alleviation of fever was observed between the two groups. Based on a cycling probe real-time polymerase chain reaction (PCR) assay, none of the A(H1N1)pdm09 strains in this study had the H275Y mutation conferring oseltamivir resistance. Further evaluation of the clinical effectiveness of the newly released NAIs for influenza-infected patients, including those infected with A(H1N1)pdm09, is needed.</abstract><cop>Japan</cop><pub>Elsevier Ltd</pub><pmid>22644080</pmid><doi>10.1007/s10156-012-0428-1</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-321X |
| ispartof | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2012, Vol.18 (6), p.858-864 |
| issn | 1341-321X 1437-7780 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1273452709 |
| source | MEDLINE; SpringerNature Journals; Alma/SFX Local Collection |
| subjects | Antiviral Agents - therapeutic use Child Child, Preschool Clinical effectiveness Cyclopentanes - therapeutic use Disease Outbreaks Enzyme Inhibitors - therapeutic use Female Fever alleviation Guanidines - therapeutic use Hematology, Oncology and Palliative Medicine Humans Infectious Diseases Influenza A Virus, H1N1 Subtype - isolation & purification Influenza A Virus, H3N2 Subtype - isolation & purification Influenza virus Influenza, Human - drug therapy Influenza, Human - epidemiology Influenza, Human - virology Japan - epidemiology Male Medical Microbiology Medicine Medicine & Public Health Neuraminidase - antagonists & inhibitors Neuraminidase inhibitors Observational study Original Article Oseltamivir - therapeutic use Treatment Outcome Virology Zanamivir - therapeutic use |
| title | Clinical effectiveness of neuraminidase inhibitors—oseltamivir, zanamivir, laninamivir, and peramivir—for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010–2011 influenza season in Japan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T12%3A58%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20effectiveness%20of%20neuraminidase%20inhibitors%E2%80%94oseltamivir,%20zanamivir,%20laninamivir,%20and%20peramivir%E2%80%94for%20treatment%20of%20influenza%20A(H3N2)%20and%20A(H1N1)pdm09%20infection:%20an%20observational%20study%20in%20the%202010%E2%80%932011%20influenza%20season%20in%20Japan&rft.jtitle=Journal%20of%20infection%20and%20chemotherapy%20:%20official%20journal%20of%20the%20Japan%20Society%20of%20Chemotherapy&rft.au=Shobugawa,%20Yugo&rft.date=2012&rft.volume=18&rft.issue=6&rft.spage=858&rft.epage=864&rft.pages=858-864&rft.issn=1341-321X&rft.eissn=1437-7780&rft_id=info:doi/10.1007/s10156-012-0428-1&rft_dat=%3Cproquest_cross%3E1273452709%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1273452709&rft_id=info:pmid/22644080&rft_els_id=S1341321X12702118&rfr_iscdi=true |